Appoints Euan MacIntyre, Ph.D. as Senior Vice President of Drug Discovery
HAYWARD, Calif., Oct. 29 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biopharmaceutical company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today named D. Euan MacIntyre, Ph.D., to the newly-created position of Senior Vice President, Drug Discovery. Dr. MacIntyre brings over 20 years of pharmaceutical drug discovery and development leadership to Arete Therapeutics.
"We are extremely pleased to welcome Euan as a member of our executive management team, as his broad drug discovery expertise and disease-specific knowledge will bolster our ability to develop effective s-EH inhibitors," said James H. Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "Given his scientific accomplishments and exceptional track record in advancing discovery programs through clinical development, I am confident Euan will provide invaluable insights and leadership as we finalize our plans to initiate a phase II study of AR9281 to treat metabolic syndrome and build out our expertise in this unique area of biology."
Dr. MacIntyre comes to Arete after more than 22 years with Merck
Research Laboratories, where he held positions of escalating importance,
most recently as Vice President of Pharmacology. Under his leadership, Dr.
MacIntyre's team identified and validated several compounds now
commercially available or in clinical trials for a variety of diseases and
conditions including emesis, diabetes, obesity, hypertension,
hyperlipidemia, pain, urinary incontinence and immuno-inflammatory
disorders. In addition to his experience in discovery and development, Dr.
MacIntyre evaluated numerous in-licensing candidates and served as a member
of several joint research committees for Merck's joint ventures and
collaborations. Dr. MacIntyre received his Ph.D. in pharmacology and
experimental pathology from the University of Cambridge. H
|SOURCE Arete Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved